PEL

Piramal Enterprises Limited has informed the Exchange regarding a press release dated May 03, 2013, titled "Piramal Enterprises announces Q4 and full year FY2013 result; the Board of Directors has recommended a dividend of Rs. 17.5 per equity share (875%) for FY2013".

Piramal Enterprises Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 01, 2013, has appointed following as Directors of the Company: (1) Mr. Siddharth Mehta - Non-Executive Independent Director. (2). Mr. Gautam Banerjee - Non-Executive Director.

Piramal Enterprises Limited has informed the Exchange regarding the Outcome of Court Convened Meeting and Extraordinary General Meeting of the Shareholders of the Company under Clause 35A.

Piramal Enterprises Limited has informed the Exchange that by an Order made on February 01, 2013, in the above Company Summons for Direction, the Hon ble High Court of Judicature at Bombay has directed that a meeting of the Equity Shareholders of the Company, be convened and held on March 13, 2013 for the purpose of considering and if thought fit, approving with or without modification(s), the proposed arrangement embodied in the Scheme of Amalgamation and Arrangement between PHL Holdings Private Limited and Piramal Enterprises Limited and their respective shareholders and creditors ( the Sche

Piramal Enterprises Limited has informed the Exchange regarding a press release dated February 11, 2013, titled "Piramal Enterprises announces Q3 FY2013 result".

Piramal Enterprises Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended December 31,2012.

Piramal Enterprises Limited has informed the Exchange regarding a press release dated December 03, 2012, titled "Piramal Enterprises' Subsidiary, Decision Resources Group, Acquires Abacus International".

Piramal Enterprises Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on November 05, 2012.

Piramal Enterprises Limited has informed the Exchange regarding a press release dated November 05, 2012, titled "Piramal Enterprises announces Q2 FY2013 result".

Piramal Enterprises Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with Limited Review Report for the period ended September 30,2012.

PHL Holdings Private Limited has has submitted to the Exchange vide letter dated October 30, 2012 a copy of Disclosure under Regulation 29(1) and 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Share and Takeovers) Regulations, 2011 ('SEBI Takeover Regulation') along with a copy of Disclosure under Regulation 13(4A) and 13(3) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 ('SEBI Insider Trading Regulations').

BMK Laboratories Private Limited has submitted to the Exchange vide letter dated October 30, 2012 a copy of Disclosure under Regulation 13(3),13(4), 13(4A) and 13(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.

Paramount Pharma Private Limited has submitted to the Exchange vide letter dated October 30, 2012 a copy of Disclosure under Regulation 13(3),13(4), 13(4A) and 13(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.

Cavaal Fininvest Private Limited has submitted to the Exchange vide its letter dated October 30, 2012 a copy of Disclosure under Regulation 13(3), 13(4), 13(4A) and 13(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.

Piramal Enterprises Limited has submitted to the Exchange vide letter dated November 01, 2012 a copy of Disclosure under Regulation 13(4A), 13(3) and 13(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.

Piramal Enterprises Limited has submitted to the Exchange vide letter dated November 01, 2012 a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Members of the Exchange are hereby informed that the name of Piramal Healthcare Limited shall be changed to Piramal Enterprises Limited and the trading symbol of the Company be changed from PIRHEALTH to PEL w.e.f. September 21, 2012

News Verification : The media had reports that Piramal Healthcare Limited is in talks with Ind-Swift Laboratories Limited to acquire contract research and manufacturing business. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Healthcare Limited has vide its letter inter-alia stated, " We would like to clarify that as a fast growing company, Piramal Enterprises Limited (Formerly known as Piramal Healthcare Limited) explores

Piramal Healthcare Limited has informed the Exchange regarding a press release dated August 14, 2012, titled "Piramal Enterprises announces Q1 FY2013 result".

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 71029 lacs for quarter ending on 30-JUN-2012 against Rs. 43500 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. 408 lacs for the quarter ending on 30-JUN-2012 against Rs. 8923 lacs for the quarter ending on 30-JUN-2011.

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 33404 lacs for quarter ending on 30-JUN-2012 against Rs. 29023 lacs for the quarter ending on 31-MAR-2012. Net Profit / (Loss) of Rs. 561 lacs for the quarter ending on 30-JUN-2012 against Rs. (5943) lacs for the quarter ending on 31-MAR-2012.

Piramal Healthcare Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with Limited Review Report for the period ended June 30,2012.

Piramal Healthcare Limited has informed the Exchange that the Company have received the Fresh Certificate of Incorporation Consequent upon Change of Name dated July 31, 2012 from the Registrar of Companies, Mumbai, Maharashtra, approving the change of name of the Company to "Piramal Enterprises Limited". Accordingly, the name of the Company stands changed from 'Piramal Healthcare Limited' to 'Piramal Enterprises Limited' with effect from July 31, 2012.

Piramal Healthcare Limited has informed the Exchange that Ms. Chanda Makhija Thadani, a member of the Institute of Company Secretaries of India has been appointed as Assistant Company Secretary of the Company.

Piramal Healthcare Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Shareholders of the Company held on July 19, 2012.

Piramal Healthcare Limited has informed the Exchange regarding a Press Release dated July 20, 2012, titled "Piramal Healthcare's cancer drug P276 moves to Phase II for reduction of serious radiation induced mucositis in patients of head and neck cancer receiving chemoradiation".

Piramal Healthcare Limited has submitted to the Exchange vide letter dated July 11, 2012 a copy of Disclosure under Regulation 13(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.

Piramal Healthcare Limited has informed the Exchange regarding a Press Release dated June 08, 2012 titled "Piramal Healthcare Limited Completes Acquisition of Decision Resources Group."

Piramal Healthcare Limited has informed the Exchange regarding a press release dated May 22, 2012, titled "Piramal Healthcare to Present Phase I data for oral anticancer molecule at the American Society for Clinical Oncology (ASCO) Annual Meeting".

Piramal Healthcare Limited has informed the Exchange regarding a press release dated May 16, 2012, titled "PIRAMAL HEALTHCARE LIMITED TO ACQUIRE DECISION RESOURCES GROUP".

Piramal Healthcare Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.

Piramal Healthcare Limited has informed the Exchange regarding a press release dated May 03, 2012, titled "Piramal Healthcare announces Q4 & full year FY2012 result; Board of Directors has recommended a dividend of Rs.17.5 per equity share (875%) for FY2012, increased dividend reflects confidence in inherent profitability of the Company".

Piramal Healthcare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 03, 2012, inter alia, has recommended dividend of Rs. 17.5 (Rupees Seventeen and Paise Fifty only) per equity share of face value of Rs. 2/- (i.e. @ 875%) for the financial year ended March 31, 2012.

Piramal Healthcare Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2012 as follows: Net Sales of Rs. 208383 lacs for year ending on 31-MAR-2012 against Rs. 250986 lacs for the year ending on 31-MAR-2011. Net Profit / (Loss) of Rs. 11150 lacs for the year ending on 31-MAR-2012 against Rs. 1288336 lacs for the year ending on 31-MAR-2011.

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2012 as follows: Net Sales of Rs. 109625 lacs for year ending on 31-MAR-2012 against Rs. 158536 lacs for the year ending on 31-MAR-2011. Net Profit / (Loss) of Rs. 13072 lacs for the year ending on 31-MAR-2012 against Rs. 1289691 lacs for the year ending on 31-MAR-2011.

Piramal Healthcare Limited has informed the Exchange regarding a two press releases dated April 16, 2012, titled "Piramal Healthcare Limited acquires molecular imaging development portfolio of Bayer Pharma". and "Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain".

Piramal Healthcare Limited has informed the Exchange regarding a press release dated April 11, 2012 titled "Piramal Healthcare announces approval of its first innovative product for regenerative medicine, BST-CarGel(R)".

Piramal Healthcare Limited has informed the Exchange regarding the Outcome of the Meeting of the Board of Directors of the Company held on April 02, 2012.

Piramal Healthcare Limited has submitted to the Exchange a copy of the results of the Postal Ballot in the format prescribed under clause 35A for Special Resolution pursuant to section 314 of the Companies Act 1956, for appointment of Mr. Peter D. DeYoung, who is husband of Ms. Nandini Piramal and son-in-law of Mr. Ajay G.Piramal and Dr. (Mrs.) Swati A. Piramal, Directors of the company, to hold office in the Company.

Piramal Healthcare Limited has submitted to the Exchange a copy of notice pursuant to Section 192A of the Companies Act, 1956 ("the Act") read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2011, in respect of the following Resolution to be passed through Postal Ballot : Special Resolution under section 314 of the Companies Act 1956, seeking shareholders consent for the appointment of Mr. Peter D. DeYoung, who is the husband of Ms. Nandini Piramal and son-in-law of Mr. Ajay G. Piramal and Dr. (Mrs.) Swati A. Piramal, Directors of the Company, to hold office in the Compa

Piramal Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2012 titled "Piramal Healthcare to Acquire Further 5.5% Stake in Vodafone India".

Piramal Healthcare Limited has informed the Exchange regarding a press release dated February 02, 2012 titled "Piramal Healthcare announces Q3FY2012 results, Total operating income up by 16% to Rs 618 crores,Operating Profit was Rs 37 crores and Net Profit for the quarter was Rs 10 crores".

Piramal Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2011 as follows: Net Sales of Rs. 29705 lacs for quarter ending on 31-DEC-2011 against Rs. 20980 lacs for the quarter ending on 31-DEC-2010. Net Profit / (Loss) of Rs. (633) lacs for the quarter ending on 31-DEC-2011 against Rs. 9202 lacs for the quarter ending on 31-DEC-2010.

Piramal Healthcare Limited has submitted to the Exchange the Standalone Financial Results along with Limited Review Report for the period ended December 31,2011.

Piramal Healthcare Limited has submitted to the Exchange the Consolidated Financial Results along with Limited Review Report for the period ended December 31,2011.

Piramal Healthcare Limited has informed the Exchange vide its letter dated December 21, 2011 regarding Changes in Board of Directors.

Piramal Healthcare Limited has informed the Exchange vide its letter dated December 07, 2011 regarding Results of Postal Ballot.

Piramal Healthcare Limited has informed the Exchange that the Hon'ble Bombay High Court on November 25, 2011 has sanctioned the Scheme of Arrangement for Demerger of the NCE Research Unit of Piramal Life Sciences Limited into Piramal Healthcare Limited. Shareholders of Piramal Life Sciences Limited ('PLSL') to receive the equity shares of Piramal Healthcare Limited ('PHL') in the ratio of 1:4 (i.e. one share of Rs. 2 each of PHL for every 4 shares of Rs. 10/- each held in PLSL) under the aforesaid scheme.

Piramal Healthcare Limited has submitted to the Exchange a copy of notice pursuant to Section 192A of the Companies Act, 1956 ("the Act") read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, in respect of the following Resolutions to be passed through Postal Ballot : (1) Special Resolution pursuant to section 17 of the Companies Act 1956, for amendment of the Objects Clause of the Memorandum of Association of the Company by insertion of new objects; (2) Special Resolution under section 149(2A) of the Companies Act 1956, for commencement of the businesses covered by

Piramal Healthcare Limited has informed the Exchange regarding a Press Release dated November 01, 2011, titled "Piramal Healthcare announces settlement of patent litigation with Baxter Healthcare related to generic version of SUPRANE� (Desflurane)".